Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 266Lenalidomide 159daratumumab 137Bortezomib 114pomalidomide 91Calcium Dobesilate 86Cyclophosphamide 85carfilzomib 77Specimen Handling 46isatuximab 45fludarabine 43Biopsy 43belantamab mafodotin 42Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 33talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
incomplete Freund's adjuvant × Plasma cell × 1 year × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡